Indian Drug Makers Increase Nutraceutical Activity
This article was originally published in PharmAsia News
Several Indian drug makers are expanding their nutraceutical products to take advantage of an expected explosion in the market. The pharmaceutical industry estimates the nutraceutical segment of medicine to be worth about $400 million in India, a major part of a $7 billion health care sector. An Ernst & Young partner questioned, however, whether the segment also should include ayurvedic and herbal products, which in India are considered drugs for regulatory purposes. Those products are expected to reach $190 billion in sales by 2010. Among drug makers seeking to expand are Elder Pharma, Glenmark, Plethico, Troikaa and Wockhardt. (Click here for more
You may also be interested in...
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.